PMID- 22579960
OWN - NLM
STAT- MEDLINE
DCOM- 20130110
LR  - 20161126
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1826
IP  - 2
DP  - 2012 Dec
TI  - Plasmacytoids dendritic cells are a therapeutic target in anticancer immunity.
PG  - 407-14
LID - S0304-419X(12)00033-9 [pii]
LID - 10.1016/j.bbcan.2012.04.007 [doi]
AB  - Dendritic cells (DCs) are immunological sentinels of the organism acting as 
      antigen-presenting cells (APC) and are critical for induction of innate and 
      adaptive immunity. Traditionally they are divided in myeloid dendritic cells 
      (mDCs) and plasmacytoid dendritic cells (pDCs), a rare population of circulating 
      cells that selectively express Toll-like receptors (TLR) 7 and TLR9 and have the 
      capacity to produce large amounts of type I interferons (IFNs) in response to 
      pathogenic agents or danger signals. It has been demonstrated that pDCs can 
      coordinate events during the course of viral infections, allergic and autoimmune 
      diseases and cancer. Through the production of type I IFNs, pDCs initiate 
      protective immunity by activating classical DCs, T cells, natural killer cells 
      and B cells. Upon activation, pDCs also differentiate into mature DCs and may 
      contribute to the contraction of T-cell response. Human pDCs preferentially 
      express immunoglobulin-like transcript 7 (ILT7; LILRA4), which couples with a 
      signaling adapter to activate a prominent immune-receptor tyrosine-based 
      activation motif (ITAM)-mediated signaling pathway. The interaction between ILT7 
      and bone marrow stromal cell antigen 2 (BST2, CD317) assures an appropriate TLR 
      response by pDCs during viral infections and likely participates in pDCs tumor 
      crosstalk. Moreover these cells seem to play a crucial role in the initiation of 
      the pathological process of autoimmune diseases such as lupus or psoriasis. 
      Despite the fact that their function within a tumor context is still 
      controversial they represent an attractive target for therapeutic manipulation of 
      the immune system to elicit a powerful immune response against tumor antigens in 
      combination with other therapies.
CI  - Published by Elsevier B.V.
FAU - Palma, Giuseppe
AU  - Palma G
AD  - Struttura Semplice Dipartimentale Sperimentazione Animale, Istituto Nazionale dei 
      Tumori, Naples, Italy.
FAU - De Laurenzi, Vincenzo
AU  - De Laurenzi V
FAU - De Marco, Margot
AU  - De Marco M
FAU - Barbieri, Antonio
AU  - Barbieri A
FAU - Petrillo, Antonella
AU  - Petrillo A
FAU - Turco, Maria Caterina
AU  - Turco MC
FAU - Arra, Claudio
AU  - Arra C
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120509
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (LILRA4 protein, human)
RN  - 0 (Receptors, Immunologic)
RN  - 0 (Toll-Like Receptors)
SB  - IM
MH  - Animals
MH  - Clinical Trials as Topic
MH  - Dendritic Cells/*physiology
MH  - Humans
MH  - Neoplasms/*immunology/therapy
MH  - Phenotype
MH  - Receptors, Immunologic/physiology
MH  - Signal Transduction
MH  - Toll-Like Receptors/physiology
EDAT- 2012/05/15 06:00
MHDA- 2013/01/11 06:00
CRDT- 2012/05/15 06:00
PHST- 2012/02/06 00:00 [received]
PHST- 2012/04/27 00:00 [revised]
PHST- 2012/04/28 00:00 [accepted]
PHST- 2012/05/15 06:00 [entrez]
PHST- 2012/05/15 06:00 [pubmed]
PHST- 2013/01/11 06:00 [medline]
AID - S0304-419X(12)00033-9 [pii]
AID - 10.1016/j.bbcan.2012.04.007 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 2012 Dec;1826(2):407-14. doi: 10.1016/j.bbcan.2012.04.007. 
      Epub 2012 May 9.